Filspari (sparsentan) — Point32Health
Primary immunoglobulin A nephropathy (IgAN) at risk for disease progression
Initial criteria
- Documented diagnosis of immunoglobulin A nephropathy confirmed by kidney biopsy
- Documented urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g
- Documented estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
- Prescribed by or in consultation with a nephrologist
- Documentation that the patient has not developed end stage renal disease by requiring either dialysis or a kidney transplant
Reauthorization criteria
- Documented diagnosis of immunoglobulin A nephropathy confirmed by kidney biopsy
- Prescribed by or in consultation with a nephrologist
- Documentation of a positive clinical response as evidenced by a reduction in proteinuria
- Documentation that the patient has not developed end stage renal disease by requiring either dialysis or a kidney transplant
Approval duration
initial 9 months, reauth 12 months